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introduction/aim: We analyzed the functional and oncologic outcomes of primary 
and salvage transoral robotic surgery (TORS) procedures, performed in three Belgian 
institutions with a similar philosophy.
Patients and methods: A total of 86 patients who underwent TORS between 24-12-
2009 and 25-09-2015 were retrospectively reviewed. Descriptive statistics, overall 
survival (OS), disease-specific survival (DSS), and disease-free survival (DFS; Kaplan–
Meier), and the variation of these outcomes according to whether patients had primary 
or salvage TORS were evaluated (univariate log-rank analysis).
results: Of 86 patients, 56 (65.1%) underwent TORS as a primary treatment and 30 
(34.9%) as a salvage procedure for recurrent or second primary cancer. Tumor location 
was mainly oropharynx (N = 63; 73.3%) followed by supraglottic larynx (N = 11; 12.8%), 
hypopharynx (N = 11; 12.8%), and glottic larynx (N = 1; 1.2%). In the up-front TORS 
group, most tumors were classified as cT1 (N = 23; 41.1%)/pT1 (N = 24; 42.9%) or cT2 
(N = 27; 48.2%)/pT2 (N = 27; 48.2%) and cN0 (N = 18; 32.1%), cN1 (N = 13; 23.2%), 
or cN2 (N = 25; 44.6%). In the salvage TORS group, most tumors were cT1-rT1 (N = 18; 
60.0%)/pT1-rpT1 (N = 18; 60.0%) or cT2-rT2 (N = 12; 40.0%)/pT2-rpT2 (N = 7; 23.3%) 
and cN0 (N = 25; 83.3%). Neck dissection was performed in 87.5% of primary cases 
and 30.0% of salvage cases. In the up-front TORS group, patients were postoperatively 
submitted to follow-up (N =  13; 23.2%) or received adjuvant radiotherapy, either as 
single modality (N = 26; 46.4%) or with concomitant cisplatin (N = 15; 26.8%). On the 
other hand, most salvage TORS patients did not receive any adjuvant therapy (N = 19; 
63.3%). Mean and median follow-up was 23.1 and 21.2 months, respectively. Functional 
results were excellent (no definitive tracheostomy, long-term tube feeding in 1.8% of 
primary cases, and 20% of salvage cases). In the up-front TORS group, estimated 
2-year OS was 88.5% (SE = 5.0%), 2-year DSS was 91.8% (SE = 4.6%) and 2-year 
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inTrODUcTiOn
Classic open “en bloc” surgical treatment of most head and neck 
malignancies is often associated with considerable mutilation 
and functional adverse effects regarding speech, swallowing 
function, and respiration, leading to decreased quality of life. 
Since the early nineties, various “landmark studies” have 
assessed non-surgical treatment for advanced-stage head and 
neck cancer, including advanced laryngeal, hypopharyngeal, 
and oropharyngeal squamous cell carcinoma (SCC). These 
studies evaluated “organ preservation protocols,” such as induc-
tion chemotherapy and subsequent radiotherapy (RT) (1, 2) 
or more recently concurrent chemoradiation (CRT) (3, 4) and 
reported oncologic results comparable to those obtained by 
the classic combination of surgery and postoperative RT. These 
findings induced a paradigm shift away from open ablative sur-
gery toward organ preservation protocols with curative intent 
over the last decades (5). It is obvious that these non-surgical 
treatment protocols are associated with less mutilation when 
compared with classic open resections of advanced head and 
neck malignancies. However, major functional complications 
(dysarthria/dysphonia, trismus, dysphagia, xerostomia, dysp-
nea, and stridor) are not uncommon. This implies that these 
organ preservation strategies do not translate into an adequate 
function preservation for all treated patients (6–8). Although 
transoral laser microsurgery (TLM) has been, mainly in Europe, 
a valid minimally invasive surgical technique to address selected 
malignancies of the upper aerodigestive tract since its introduc-
tion in the 1980s, it is the recent introduction of transoral robotic 
surgery (TORS), which has revived the interest to treat a selection 
of head and neck malignancies surgically through a minimally 
invasive approach. The underlying idea is that a combination of 
less invasive surgical removal of tumors, that allows a less toxic 
non-surgical adjuvant therapy, would combine a disease control 
rate comparable to non-surgical organ preservation strategies 
with more satisfying functional results. TORS for treatment of 
head and neck malignancies was introduced in 2006 and has 
become well established in recent years, especially for the resec-
tion of early-stage oropharyngeal or supraglottic SCC, yielding 
excellent oncologic and functional outcomes. This makes 
primary TORS a possible alternative to non-surgical organ 
preservation regimens (9–18). Also for recurrent oropharyngeal 
carcinoma after primary (chemo)radiotherapy, there are reports 
that salvage TORS may yield better functional results when com-
pared to radical open salvage surgery (19). In this multicenter 
retrospective case series, we reviewed functional and oncologic 
outcomes of primary or up-front and salvage TORS procedures 
performed in three Belgian hospitals.
PaTienTs anD MeThODs
Patients
This study was approved by and carried out in accordance 
with the recommendations of the Institutional Review Board 
(University Hospital Leuven Committee for Medical Ethics: 
IRB study number s58234). Informed consent for retrospective 
studies with anonymized data is not required according to 
Belgian law.
All consecutive (n = 86) patients with malignant head and 
neck neoplasms who were selected to undergo TORS between 
24-12-2009 and 25-09-2015 were included in this multicenter 
retrospective case series. TORS was performed in three Belgian 
medical institutions: the University Hospitals of Leuven 
(Leuven, Belgium), the General Hospital AZ Sint-Lucas (Ghent, 
Belgium), and the General Hospital AZ Sint-Jan (Bruges, 
Belgium). The decision to submit a patient with a head and neck 
malignancy to TORS always resulted from discussion during 
a multidisciplinary tumor board meeting. Prior to surgery, 
patients were, according to the tumor board advice, properly 
staged and screened for distant disease. Tumor stage was 
determined according to the Union for International Cancer 
Control seventh edition staging system for malignant head and 
neck tumors (20).
Treatment
Transoral robotic resection of tumors was performed using 
either the Da Vinci S or Da Vinci Si system (Intuitive Surgical 
Inc., Sunnyvale, CA, USA). Transoral exposure of the tumor 
was achieved using the Feyh-Kastenbauer retractor (Gyrus, 
Tuttlingen, Germany), Crowe-Davis retractor, or the laryngeal 
advanced retractor system (Fentex, Tuttlingen, Germany). The 
Da Vinci system was equipped with a 5 mm Maryland dissector 
and 5 mm monopolar spatula. Resection of the tumor was per-
formed in accordance with general oncologic principles, always 
aiming for a complete tumor removal. In patients with clinically 
DFS was 86.1% (SE = 5.3%). In the salvage TORS group, estimated 2-year OS was 
73.5% (SE = 10.9%), 2-year DSS was 93.3% (SE = 6.4%), and 2-year DFS was 75.8% 
(SE = 9.7%). Comparing outcome of primarily treated patients to salvage patients, a 
non-statistically significant trend toward better OS (p = 0.262) and DFS (p = 0.139) was 
observed.
conclusion: This retrospective study confirms favorable oncologic and functional out-
comes of TORS for selected head and neck malignancies, both in the primary and in the 
salvage setting.
Keywords: transoral robotic surgery, squamous cell carcinoma, oropharyngeal cancer, supraglottic cancer, 
salvage surgery
TaBle 1 | Overview of patient demographics, histology, hPV status, and 
transoral robotic surgery (TOrs) indication.
characteristic Value (N = 86) %
age, mean (sD), years 63 (9.7)
sex
Male 65 75.6
Female 21 24.4
smoking history
Yes (active or past) 63 73.2
No 11 12.8
Unknown 12 14.0
alcohol use
Active abuse (≥5 U/day) 19 22.1
Daily drinker (<5 U/day) 36 41.9
Occasional drinker 15 17.4
Past abuse 3 3.5
Unknown 13 15.1
histology
Squamous cell carcinoma 83 96.5
Mucoepidermoid carcinoma 1 1.2
Mucinous cystadenocarcinoma 1 1.2
Primary laryngeal carcinoid tumor 1 1.2
P16 staining (19 tested)
Positive 11 57.9
Negative 8 42.1
hPV ish (29 tested)
Positive 11 37.9
Negative 18 62.1
TOrs indication
Up-front (primary) TORS 56 65.1
Salvage TORS 30 34.9
HPV, human papillomavirus; ISH, in situ hybridization.
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positive neck nodes and in patients with high risk (≥20%) for 
occult nodal involvement, neck dissections (uni- or bilateral) 
were performed immediately before or after the TORS procedure 
or as a second-stage procedure. In patients who presented with 
a clinically and radiographically negative neck who underwent 
prior irradiation of the neck, a watchful waiting policy was pre-
ferred. When deemed necessary by the senior surgeons (CVC, 
TV, and VVP), a nasogastric (NG) feeding tube was placed after 
the procedure to facilitate caloric intake in the immediate post-
operative phase. A tracheotomy was only performed in those 
cases at risk for developing breathing problems postoperatively 
due to airway edema. Resection specimens were oriented and 
sent to the pathologist. In case of oropharyngeal SCC (OPSCC), 
human papilloma virus (HPV) status was assessed either by p16 
immunostaining or by HPV in  situ hybridization, depending 
on the institution where surgery was performed. Following 
surgical treatment and pathologic examination of the resection 
specimen, the patients were rediscussed during the multidis-
ciplinary tumor board meeting before any adjuvant therapy 
[RT, CRT, additional surgery, or photodynamic therapy (PDT)] 
was administered. Adjuvant therapy was reserved for patients 
with adverse pathological features, including advanced T and/
or N status, positive or close surgical margins, extracapsular 
nodal involvement, perineural invasion, and lymphovascular 
invasion. After termination of treatment, regular follow-up 
visits were organized every 2  months during the first 2  years, 
every 3 months during the third year, every 4 months during 
the fourth year, and every 6 months thereafter. Baseline imag-
ing of the neck (CT or MRI) was performed 3–4 months after 
treatment and was repeated 1  year after treatment to exclude 
locoregional recurrence (21). Yearly imaging of the chest (plain 
chest radiograph or CT chest) was performed in order to detect 
lung metastases.
Data and statistical analysis
Anonymized data were retrospectively collected from the three 
participating centers and pooled in a central structured electronic 
database. These data were related to patient and tumor character-
istics, treatment, oncologic outcomes, and functional outcomes. 
Data were analyzed using SPSS version 22.0 statistical software 
(IBM Corp., Armonk, NY, USA). Descriptive statistics were 
used to represent data where applicable. Fisher’s exact test with 
Freeman–Halton extension was used to compare margin status 
between the primary and salvage group in a 2 × 3 contingency 
table. Kaplan–Meier methods were used to estimate overall 
survival (OS), disease-free survival (DFS), and disease-specific 
survival (DSS) and univariate analysis using log-rank testing was 
employed to compare these survival data between subgroups 
(primary surgery group versus salvage surgery group). Statistical 
significance was defined at the p < 0.05 level.
resUlTs
Patient characteristics
In this multi-institutional case series, 86 patients who underwent 
TORS were included. The population consisted of 65 males 
(75.6%) and 21 females (24.4%). Mean age at the time of TORS 
procedure was 63.4 years. Of the 74 patients with known smok-
ing status, 63 (85.1%) were active or former smokers, while 11 
patients (14.9%) had never smoked. Concerning alcohol use, data 
of 73 patients were obtained. Of these patients, 55 (75.3%) were 
active daily drinkers, 15 (20.5%) were occasional drinkers, and 3 
(4.1%) had quit drinking. Patient demographics are summarized 
in Table 1.
Treatment characteristics
Of the 86 patients treated with TORS, 56 (65.1%) underwent 
TORS as an up-front treatment and 30 (34.9%) were treated in a 
salvage setting for recurrent or second primary cancer. TORS for 
salvage treatment of a second primary head and neck cancer after 
the patient had been treated previously for another head and neck 
cancer was performed in 20 cases (66.7% of salvage cases), while 
10 patients (33.3% of salvage cases) underwent TORS for salvage 
treatment of a local recurrence after primary surgery (N = 1), RT 
(N = 3), CRT (N = 4), or a combination of surgery and RT or 
CRT (N = 2).
Neck dissection was performed in the majority of up-front 
TORS cases (N = 49 or 87.5%), but was not frequent in salvage 
cases who only underwent neck dissection in case of cN + status 
(N = 9 or 30.0%). Neck dissection was most often combined with 
characteristic Value (N = 56) %
Clinical tumor classification
 cT0 Oropharynx 1 1.8
 cT1 23 41.1
  Oropharynx 17
  Supraglottic larynx 3
  Hypopharynx 3
 cT2 27 48.2
  Oropharynx 24
  Supraglottic larynx 2
  Hypopharynx 1
 cT3 4 7.1
  Oropharynx 3
  Hypopharynx 1
 cT4a Oropharynx 1 1.8
Clinical nodal classification
 cN0 18 32.1
 cN1 13 23.2
 cN2 25 44.6
Neck dissection
 Yes 49 87.5
  Levels I–III 4
  Levels II–III 1
  Levels II–IV 10
  Levels I–IV 4
  Levels II–V 10
  Levels I–V 20
 No 7 12.5
Surgical margin status
 Clear 21 37.5
 Close (<5 mm) 10 17.9
 Positive 24 42.9
 Second primary in margin 1 1.8
Pathological tumor classification
 pT1 24 42.9
  Oropharynx 18
  Supraglottic larynx 3
  Hypopharynx 3
 pT2 27 48.2
  Oropharynx 25
  Supraglottic larynx 1
  Hypopharynx 1
 pT3 2 3.6
  Oropharynx 1
  Hypopharynx 1
 pT4 2 3.6
  Oropharynx 1
  Hypopharynx 1
 pR2 (macroscopic residual tumor) (oropharynx) 1 1.8
Pathological nodal classification
 pNx 7 12.5
 pN0 15 26.8
 pN1 11 19.6
 pN2a 7 12.5
 pN2b 16 28.6
 pN2c 0
Adjuvant treatment
 No adjuvant treatment, follow-up 13 23.2
 Radiotherapy 26 46.4
 Chemoradiotherapy 15 26.8
 Surgery (TLM) + radiotherapy 1 1.8
 Undetermined (early death) 1 1.8
TLM, transoral laser microsurgery.
TaBle 2 | Overview of treatment and tumor characteristics for the 
up-front transoral robotic surgery group (N = 56).
characteristic Value (N = 56) %
Subsite
 Oropharynx 46 82.1
  Base of tongue 9
  Tonsil 32
  Posterior wall 1
  Vallecula 2
  Glossotonsillar sulcus 1
  Retromolar trigone 1
 Supraglottic larynx 5 8.9
  Epiglottis 3
  Aryepiglottic fold 1
  Unknown 1
 Hypopharynx (pyriform sinus) 5 8.9
(Continued )
TaBle 2 | continued
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TORS in a one-stage procedure (N = 51) versus as a second-stage 
procedure (N = 7).
Mean hospital stay was 6.8  days (median 5  days, range 
2–33  days, SD 5.9  days) in the up-front TORS group versus 
9.3 days (median 7 days, range 2–67 days, SD 11.8 days) in the 
salvage group.
No patients received neoadjuvant treatment prior to TORS. 
Concerning adjuvant strategy, two patients died in the postopera-
tive phase before any adjuvant strategy was decided upon. In the 
up-front TORS group, patients were postoperatively submitted 
to follow-up (N = 13; 23.2%) or received adjuvant RT, either as 
single modality (N = 26; 46.4%) or with concomitant cisplatin 
(N = 15; 26.8%). One patient underwent a combination of salvage 
TLM and RT. On the other hand, most salvage TORS patients did 
not receive any adjuvant therapy (N = 19; 63.3%). Adjuvant RT 
and CRT were administered in 4 (13.3%) and 2 (6.7%) salvage 
patients, respectively. Two other salvage patients (6.7%) under-
went salvage surgery (TLM in one case and total laryngectomy 
in one case), and two other patients (6.7%) were treated with 
postoperative PDT because of involved resection margins after 
TORS procedure for recurrent SCC of the base of tongue after 
primary RT or CRT (22). Detailed data on neck dissection and 
adjuvant strategy for both the up-front and salvage groups are 
depicted in Tables 2 and 3.
In the up-front TORS group, eight complications and adverse 
events (intraoperative, early postoperative/in-hospital, and late 
postoperative) were encountered. These were intraoperative 
accidental perforation of the aerodigestive tract eventually 
leading to fistula formation (N =  1), prolonged pain (N =  1), 
pneumonia (N = 1), lingual edema (N = 1), acute myocardial 
infarction (N = 2 of whom one patient died 10 days after TORS), 
and respiratory collapse (N = 2 of whom one patient with known 
COPD and restrictive lung disease due to severe scoliosis died 
at postoperative day 30). In the salvage group, 13 complications 
and adverse events were registered. Teeth abrasion was encoun-
tered intraoperatively in two patients. Early treatment-related 
complications and adverse events (during hospitalization) were 
respiratory collapse (N =  2 of whom one died), temporarily 
characteristic Value (N = 30) %
Adjuvant treatment
 No adjuvant treatment, follow-up 19 63.3
 Radiotherapy 4 13.3
 Chemoradiotherapy 2 6.7
 Photodynamic therapy 2 6.7
 Surgery (TLM, total laryngectomy) 2 6.7
 Undetermined (early death) 1 3.3
TLM, transoral laser microsurgery.
TaBle 3 | Overview of treatment and tumor characteristics for the 
salvage transoral robotic surgery group (N = 30).
characteristic Value (N = 30) %
Reason for salvage surgery
 Local recurrence 10 33.3
 Second primary tumor 20 66.7
Subsite
 Oropharynx 17 56.7
  Base of tongue 8
  Tonsil 2
  Posterior wall 3
  Vallecula 2
  Soft palate 2
 Supraglottic larynx 6 20.0
  Epiglottis 5
  Aryepiglottic fold 1
 Hypopharynx (pyriform sinus) 6 20.0
 Glottic larynx 1 3.3
Clinical tumor classification
 cT1/rT1 18 60.0
  Oropharynx 8
  Supraglottic larynx 4
  Hypopharynx 6
 cT2/rT2 12 40.0
  Oropharynx 9
  Supraglottic larynx 2
  Glottic larynx 1
Clinical nodal classification
 cN0 25 83.3
 cN1 3 10.0
 cN2 2 6.7
Neck dissection
 Yes 9 30.0
  Superselective neck dissection (1 or 2 levels) 3
  Levels II–V 5 (1 bilateral)
  Levels II–IV 1 (bilateral)
 No 21 70.0
Surgical margin status
 Clear 10 33.3
 Close (<5 mm) 8 26.7
 Positive 10 33.3
 Not assessable (coagulation artifacts) 2 6.7
Pathological tumor classification
 pT0/rpT0 oropharynx 1 3.3
 pT1/rpT1 18 60.0
  Oropharynx 9
  Supraglottic larynx 5
  Hypopharynx 4
 pT2/rpT2 7 23.3
  Oropharynx 5
  Supraglottic larynx 1
  Hypopharynx 1
 pT4/rpT4 glottic larynx 1 3.3
 pTx/rpTx (not specified) 3 10.0
Pathological nodal classification
 pNx 21 70.0
 pN0 3 10.0
 pN1 3 10.0
 pN2a 0
 pN2b 2 6.6
 pN2c 1 3.3
(Continued )
TaBle 3 | continued
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nasal regurgitation of food (N = 1), fistula formation (N = 1), 
serious dysphagia and aspiration, necessitating total laryngec-
tomy (N = 1), and postoperative hemorrhage needing surgical 
revision (N =  1). Late treatment-related complications (after 
hospital discharge) were encountered in five salvage patients: 
one patient developed necrosis of the posterior oropharyngeal 
wall and spondylitis/spondylodiscitis of C3–C4 4 months after 
TORS, one patient who underwent robotic oropharyngectomy 
developed osteomyelitis of the clivus and right petrous apex 
2 years after surgery, one patient developed late aspiration and 
weight loss necessitating gastrostomy tube (G-tube) placement 
5  months after TORS, and two patients developed necrosis of 
the resection site of whom one evolved to a late carotid blowout 
and subsequent death (11 months after TORS). Concerning the 
three treatment-related, early/in-hospital deaths, a lethal myo-
cardial infarction occurred in one patient at postoperative day 
10 and would probably also have occurred if a classical surgical 
procedure had been carried out. The patient had undergone a 
thorough preoperative anesthesiologic checkup including ECG 
and the patient was considered medically fit for surgery. One of 
two patients with a fatal respiratory collapse had a salvage oro-
hypopharyngectomy that did not interfere with the laryngeal 
airway; it was deemed that a tracheostomy was not necessary on 
the condition of a nil-by-mouth regimen. Although there were 
no signs of aspiration in the first 24 h and the patient was on 
intravenous antibiotics, the patient developed a fulminant atypi-
cal bilateral upper and lower lobe pneumonia, uncontrollable 
despite performing a tracheostomy at 24 h postoperatively, arti-
ficial ventilation, and antibiotic therapy. The patient succumbed 
to this evolution. In retrospect, an up-front tracheostomy may 
have prevented this, but the postoperative course remains dif-
ficult to explain. The second patient who died from respiratory 
problems had severe COPD and restrictive lung disease related 
to severe scoliosis. He underwent an up-front transoral resection 
of a small cT1 SCC of the base of tongue and because of the 
limited resection, no tracheotomy was performed. The patient 
continued to need ventilatory assistance postoperatively, eventu-
ally leading to death at postoperative day 30. Taken these cases 
into consideration, a thorough preoperative evaluation of the 
cardiorespiratory condition and low threshold for performing 
a tracheotomy (especially in salvage cases) are necessary for 
reducing unfavorable outcomes.
Treatment characteristics are presented in detail in Table  2 
(up-front TORS group) and Table 3 (salvage TORS group).
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Tumor characteristics
Tumor location was mainly oropharynx (N = 63; 73.3%) and to 
a lesser extent supraglottic larynx (N = 11; 12.8%), hypopharynx 
(N = 11; 12.8%), and glottic larynx (N = 1; 1.2%). Patients were 
preoperatively classified as cT0 (N  =  1; 1.2%) (no apparent 
disease after primary excision biopsy elsewhere), cT1 (N = 41; 
47.7%), cT2 (N =  39; 45.4%), cT3 (N =  4; 4.7%), and cT4a 
(N = 1; 1.2%). Concerning the neck, classification was cN0 in 
43 patients (50.0%), cN1 in 16 patients (18.6%), and cN2 in 27 
patients (31.4%). All but one N2 patients presented with uni-
lateral nodal involvement (N2a/N2b). Patients were definitively 
classified as pT0/rpT0 (N = 1; 1.2%), pT1/rpT1 (N = 42; 48.8%), 
pT2/rpT2 (N =  34; 39.5%), pT3/rpT3 (N =  2; 2.3%), pT4a/
rpT4a (N = 3; 3.5%), pR2 (N = 1, 1.2%), and pTx/rpTx (N = 3, 
3.5%). Concerning the neck, classification was pNx in 28 patients 
(32.6%), pN0 in 18 patients (20.9%), pN1 in 14 patients (16.3%), 
pN2a in 7 patients (8.1%), pN2b in 18 patients (20.9%), and 
pN2c in 1 patient (1.2%). Detailed data on location, cTNM, and 
pTNM classification for both the up-front and salvage groups are 
depicted in Tables 2 and 3.
On definitive pathologic examination, the vast majority of 
operated head and neck neoplasms proved to be SCC (N = 83, 
96.5%). Minor salivary gland mucoepidermoid carcinoma and 
mucinous cystadenocarcinoma were diagnosed each in one 
case. A primary laryngeal carcinoid tumor was observed in one 
patient with a supraglottic neoplasia. HPV status was assessed in 
39 of 46 OPSCC cases treated by up-front TORS by either p16 
immunostaining or HPV ISH. Of these 39 assessed tumors, 22 
(56.4%) were considered HPV related. Of the 17 oropharyngeal 
cancers who underwent salvage surgery, HPV status was assessed 
in nine cases, which all proved HPV negative.
Concerning surgical margin assessment on definitive 
pathologic examination, clear margins were obtained in 37.5% 
(N = 21) of primary cases and 33.3% (N = 10) of salvage cases and 
close margin status was apparent in 17.9% (N = 10) and 26.7% 
(N = 8), respectively. However, margins were judged positive in 
42.9% (N = 24) of primary cases and 33.3% (N = 10) of salvage 
cases, yielding a positive margin rate in the overall population of 
39.5% (N = 34). In two salvage cases, margins were not assess-
able due to excessive coagulation artifacts. Interestingly, in one 
primary case, a small second primary tumor involved the section 
margins of a radically removed primary tumor. No statistically 
significant difference in margin status between the primary and 
salvage groups was observed (p =  0.63, Fisher’s exact test with 
Freeman–Halton extension). Margin status for both the up-front 
TORS group and salvage TORS group are illustrated in Tables 2 
and 3 respectively. Positive margin status was the only adverse 
factor leading to the decision to apply adjuvant treatment in 18 
out of 56 up-front TORS cases (32.1%).
Functional Outcome
Data concerning necessity for feeding-tube placement were avail-
able in 85 cases. The majority of up-front TORS patients (N = 38, 
69.1%) did not need a feeding tube (NG nor gastrostomy tube) 
in the immediate postoperative period. To the contrary, only 12 
salvage patients (40%) were allowed to continue oral feeding 
after TORS. A NG tube was placed in 17 up-front cases (30.9%) 
and 12 salvage cases (40%), which was removed after a mean 
duration of 3.2 days (median 3 days, range 2–7 days, SD 1.4 days) 
and 5  days (median 5  days, range 1–15  days, SD 3.8  days), 
respectively. Removal of the NG feeding tube was determined 
by the ability of the patients to achieve a normal oral daily 
caloric intake. Four salvage patients (13.3% of salvage group) 
suffered from severe dysphagia in the preoperative period and 
were dependent on a G-tube for their daily caloric intake before 
TORS. All these patients were salvage cases who underwent 
prior head and neck surgery (N = 1) or a combination of surgery 
and adjuvant RT (N = 3). They all remained G-tube dependent 
after TORS. In the postoperative phase, two salvage patients and 
one up-front patient (pT3N2bM0 with adjuvant RT) developed 
severe dysphagia with aspiration immediately after TORS and 
no subsequent favorable clinical evolution, necessitating long-
term G-tube feeding. As one can expect, swallowing outcomes 
in terms of G-tube dependency seem favorable in the up-front 
TORS group (1.8% G-tube dependency) when compared to 
the salvage group (20% G-tube dependency including G-tubes 
already present before TORS).
Concerning postoperative airway management, tracheotomy 
was deemed necessary in one up-front TORS case (1.8% of up-
front population) and in seven salvage cases (23.3% of salvage 
population). The average duration of tracheotomy presence was 
10 and 19 days (median 11 days, range 2–75 days, SD 25.1 days), 
respectively. The outlier (tracheotomy presence of 75 days) was 
a patient for whom it was decided to preserve the tracheotomy 
until completion of adjuvant PDT. No unforeseen tracheotomies 
in the postoperative phase were necessary. Main indication for 
tracheotomy was location of the tumor in the supraglottic larynx 
and base of tongue, especially in the salvage setting (five out of 
eight tracheotomies).
Oncologic Outcome and survival
Mean and median follow-up length for the total population was 
23.1 and 21.2 months, respectively (range 0.2–55.1 months, SD 
15.4  months). Mean and median follow-up for the population 
alive at the end of follow-up was 24.5 and 21.7 months, respec-
tively (range 0.3–55.1 months, SD 15.5 months). Death occurred 
in 16 patients (18.6% of total population). In the up-front 
TORS group, death occurred in 10 patients during follow-up: 
two deaths resulted from early or in-hospital treatment-related 
complications (cf. Treatment Characteristics). Local/locoregional 
recurrence and distant disease were responsible for one and four 
deaths, respectively, and in three patients, death was considered 
non-disease and non-treatment related. In the salvage TORS 
group, six deaths were encountered during follow-up, with one 
death due to an early in-hospital treatment-related complication 
and one death due to a late treatment-related complication (cf. 
Treatment Characteristics). Local recurrence was responsible 
for two deaths and another two deaths were considered neither 
non-disease nor treatment related.
Concerning disease control in the up-front group, one patient 
developed regional recurrence, one developed locoregional 
recurrence, and five patients were affected by distant disease. 
In  the salvage group, two patients developed local recurrence, 
two regional recurrence, and two were affected by distant 
FigUre 1 | Kaplan–Meier curve illustrating overall survival (Os) in patients treated with up-front or primary transoral robotic surgery (TOrs) (green) 
and salvage TOrs (blue). A trend toward better OS in the primary group is observed, although this difference is not statistically significant (log-rank test, p = 0.262).
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metastases. Looking at Kaplan–Meier survival estimates for the 
total population, estimated 2-year OS was 84.0% (SE = 4.8%), 
2-year DSS was 92.0% (SE = 3.9%), and 2-year DFS was 82.8% 
(SE = 4.8%). Estimated 2-year OS in the primarily treated group 
was 88.5% (SE =  5.0%), while the estimated 2-year OS in the 
salvage group was 73.5% (SE =  10.9%) (Figure  1). However, 
this difference was not statistically significant (log-rank test, 
p = 0.262). Estimated 2-year DSS in the primary TORS group 
was 91.8% (SE = 4.6%) and estimated 2-year DSS in the salvage 
group was 93.3% (SE = 6.4%) (Figure 2). This finding did not 
reach statistical significance (log-rank test, p = 0.677). Estimated 
2-year DFS in the primary TORS group was 86.1% (SE = 5.3%) 
and estimated 2-year DFS in the salvage group was 75.8% 
(SE = 9.7%) (Figure 3). As such, a trend toward higher disease 
control (locoregional and distant) in the primarily treated group 
was observed, though without reaching a level of significance 
(log-rank test, p = 0.139). The 2- and 3-year estimated survival 
rates are summarized in Table 4.
DiscUssiOn
Recently, TORS has been establishing itself as a valuable thera-
peutic adjunct in the treatment of head and neck cancer, and 
it is increasingly used as an alternative for conservative organ 
preservation treatments such as primary RT or CRT. Upon 
analysis of the National Cancer Database, Cracchiolo et  al. 
discovered a steep rise of patients with low T-status (T1–T2) 
OPSCC who underwent primary surgical treatment. Of 8,768 
patients in the USA with T1–T2 OPSCC, 68% underwent 
primary surgery, increasing from 56% in 2004 to 82% in 2013. 
FDA-approval of TORS treatment for early T-status OPSCC in 
2009 is considered to be the main explanation for this shift in 
treatment strategy (23). Up to now, TORS is most frequently 
applied for primary or up-front surgery of OPSCC. In this set-
ting, the TORS approach could prove advantageous for tailoring 
the adjuvant therapy strategy, which could not only result in 
downsizing adjuvant therapy but also in intensification depend-
ing on the definitive pathologic results. In a recent retrospective 
review of 76 patients who received TORS for OPSCC, up-front 
TORS deintensified adjuvant therapy: 72% of stage I/II patients 
avoided any adjuvant therapy and 46% of stage III/IV patients 
avoided CRT. Similarly, 52% of patients who would have received 
definitive RT as a single modality treatment could avoid it with 
primary surgery. On the other hand, definitive pathology after 
primary TORS resulted in intensification of adjuvant treatment 
in 33% of patients: they would have received RT alone based 
FigUre 2 | Kaplan–Meier curve illustrating disease-specific survival in patients treated with up-front or primary transoral robotic surgery (TOrs) 
(green) and salvage TOrs (blue). No difference between survival curves is observed (log-rank test, p = 0.677).
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on clinical staging, but were treated with adjuvant CRT (24). 
In this study, the authors confirmed clinical N classification and 
overall clinical stage as significant factors in predicting the need 
for adjuvant therapy after TORS, suggesting that up-front TORS 
would be most beneficial for OPSCC patients with clinical N0 
or N1 disease and those with clinical early-stage disease, making 
single modality treatment possible (24). However, in a cohort of 
2,570 patients with cT1 to cT2 and cN0 to cN1 OPSCC receiving 
up-front surgery (including TORS) who were as such candidates 
for single-modality therapy, 28% of patients were pathologically 
T- or N-upstaged and in addition 33% had positive surgical mar-
gins and/or extracapsular spread, necessitating adjuvant RT or 
even CRT in 47% of patients (23). These findings stress the need 
for optimal treatment selection, avoiding upscaling of adjuvant 
treatment. The ability of up-front TORS to downsize adjuvant 
therapy is also illustrated by Lörincz et  al. In their prospective 
cohort study, 40% of patients undergoing primary TORS did 
not need any adjuvant treatment and in another 34% of patients, 
adjuvant chemotherapy could be spared and adjuvant RT could 
be reduced (25). In the currently largest multi-institutional retro-
spective review, including 410 patients with head and neck cancer 
primarily treated by TORS, adjuvant treatment could be avoided 
in 39% of cases (26). However, a major drawback of this study was 
the multi-institutional setup, resulting in non-standardization of 
the adjuvant therapeutic strategy. In our primary surgery study 
population (N = 56), any adjuvant therapy was not indicated in 
23.2% of patients, while 26.8% did receive trimodality treatment. 
Adjuvant RT proved necessary in 46.4%.
Concerning oncologic outcomes after up-front TORS, we 
reported an estimated 2-year OS, DSS, and DFS of 88.5, 91.8, and 
86.1%, respectively. This is comparable to the 2-year OS and DSS 
of 91 and 94.5% as reported by de Almeida et al. (26) and the 
2-year OS of 89.3% as reported by White et al. (27). Lörincz et al. 
reported an OS rate of as high as 94%, but with a recurrence-free 
survival rate (including distant disease and as such identical to 
our definition of DFS) of 80% (25). In our group of patients who 
received TORS as a salvage treatment (N = 30), a 2-year OS, DSS, 
and DFS of 73.5, 93.3, and 75.8% were reported, respectively. 
These results are comparable to the 2-year OS and recurrence-
free survival of both 74% as reported in a retrospective multi-
institutional case-control study of 64 patients who underwent 
salvage TORS and 64 patients receiving salvage open surgical 
approaches for recurrent OPSCC (19). Although we observed a 
trend toward higher DFS and OS in the up-front TORS group 
when compared to the salvage TORS group, these differences 
did not reach statistical significance upon univariate analysis, 
TaBle 4 | The 2- and 3-year survival estimates in the total population, 
the primary transoral robotic surgery (TOrs) group, and the salvage 
TOrs group.
2 years 3 years
OS total population 84.0% (SE = 4.8%) 74.2% (SE = 6.3%)
OS primary 88.5% (SE = 5.0%) 78.2% (SE = 7.1%)
OS salvage 73.5% (SE = 10.9%) 64.3% (SE = 12.8%)
DSS total population 92.0% (SE = 3.9%) 86.4% (SE = 5.3%)
DSS primary 91.8% (SE = 4.6%) 87.8% (SE = 5.9%)
DSS salvage 93.3% (SE = 6.4%) 81.7% (SE = 12.3%)
DFS total population 82.8% (SE = 4.8%) 76.5% (SE = 6.2%)
DFS primary 86.1% (SE = 5.3%) 82.2% (SE = 6.4%)
DFS salvage 75.8% (SE = 9.7%) 60.6% (SE = 15.6%)
DFS, disease-free survival; DSS, disease-specific survival; OS, overall survival.
FigUre 3 | Kaplan–Meier curve illustrating disease-free survival in patients treated with up-front or primary transoral robotic surgery (TOrs) (green) 
and salvage TOrs (blue). A trend toward higher disease control (locoregional and distant) in the primary treated group is observed, though without reaching a 
level of significance (log-rank test, p = 0.139).
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confirming TORS as a valuable alternative to salvage open en 
bloc surgery. These data clearly prove the feasibility and favorable 
outcomes of TORS in this difficult to treat salvage group.
Concerning function preservation after TORS, excellent 
results were obtained in our study population. A total of 69.1% 
of up-front TORS patients and 40% of salvage TORS patients 
were able to resume an oral diet immediately after the operation. 
As one can expect, swallowing outcomes in terms of G-tube 
dependency seem favorable in the up-front TORS group (1.8% 
G-tube dependency) when compared to the salvage group 
(20% G-tube dependency). No definitive tracheotomies were 
reported. These functional outcomes are comparable to the data 
in the literature: in a recent systematic review on the topic, Yeah 
et al. identified among 13 TORS studies a feeding-tube depend-
ency rate ranging from 0 to 20.7% at 1-year postoperative 
follow-up. The rate of tracheostomy dependence among nine 
TORS studies ranged from 0 to 3.5% at 2 years postoperative 
follow-up (28).
An important issue to address is whether these oncologic and 
functional results are favorable or at least similar to the results 
obtained by organ preservation strategies. In the aforementioned 
systematic review (28), the authors concluded that, because no 
randomized trials comparing TORS versus intensity-modulated 
radiotherapy (IMRT) based regimens are currently available, only 
uncontrolled reports suggest comparable oncologic outcomes 
with TORS compared to IMRT of OPSCC, while functional out-
comes may be superior after TORS. This conclusion needs to be 
interpreted with caution, as TORS studies included patients with 
earlier stage OPSCC when compared to the IMRT population, 
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representing an important selection bias. On the other hand, 
mean follow-up of TORS studies is short when compared to 
conservative organ preservation studies, possibly favoring the 
definitive functional outcome after TORS. Moreover, direct com-
parisons of swallowing outcomes between patients treated with 
any kind of transoral surgery, including TORS, and non-surgical 
treatment is not possible because of the varying methodology 
and heterogeneity of swallowing outcome measures used (29). 
In this respect, the presumed functional superiority of TORS 
versus non-surgical treatments remains to be critically appraised 
until level I evidence will be available. Several surgical trials have 
recently begun to determine the effectiveness of transoral man-
agement of OPSCC, e.g., the ECOG3311 phase III trial compar-
ing oncologic efficacy in surgical versus non-surgical approaches 
to OPSCC, or the ORATOR phase II trial, comparing TORS to 
radiation with or without chemotherapy with quality of life as 
primary endpoint after 1  year (30). Of interest, a very recent 
retrospective stage-matched cohort study comparing OS and 
DSS and G-tube prevalence between 88 patients with OPSCC 
treated with CRT and 39 patients treated with TORS reported an 
indistinguishable survival but lower gastrostomy prevalence in 
the surgical group (31).
There are some limitations to our study. As a retrospective 
study, we are dealing with an inherent selection bias. Moreover, 
being a multi-institutional study, no standardization of decision-
making, staging, operative procedure, and adjuvant therapy can 
be guaranteed. However, all management decisions were made 
during multidisciplinary tumor board meetings. Moreover, 
because of the small study population and small subgroups, 
multivariate analysis was not possible. Moreover, we were con-
fronted with high rates of adjuvant RT or CRT in the up-front 
TORS group. This can partly be explained by selection of cT3–T4 
and cN2 patients for primary surgery. On the other hand, high 
rates of close and positive surgical margins necessitated adjuvant 
therapy. Presumably, these high rates of involved margins are 
related to the non- systematic use of frozen sections to account for 
resection radicality after TORS tumor removal on the one hand 
and to pathology assessment-related issues on the other hand. 
Regarding the latter issue, interpreting margins after electrocau-
tery resection during TORS is clearly difficult due to coagula-
tion artifacts. This may be partly overcome by using the carbon 
dioxide laser, but at the moment of the study none of the surgical 
departments disposed of a Da Vinci mountable flexible laser fiber. 
This laser resection theoretically would lead to better evaluable 
margins, but has the disadvantage of much more difficulties in 
controlling hemorrhage. Furthermore, small tumor specimen 
ruptures during TORS are not unusual due to manipulation by the 
Maryland forceps and could be misinterpreted by the pathologist 
as being a compromised margin. This finding stresses the need for 
cautious tumor manipulation and optimal communication with 
the pathologist. As a quality reinforcing measure to cut down 
future margin involvement, a new protocol for specimen orienta-
tion after resection, allowing for optimal margin assessment by 
the pathologist, has been introduced. Additionally, use of frozen 
sections in all TORS patients is heavily advocated among the 
participating centers. Another possible additional explanation 
of the high positive surgical margin rate is that this case series 
reports the first cases in all three participating centers and as 
such includes patients at the beginning of the learning curve. 
Moreover, the rather low yearly case load (86 cases during 6 years 
in three centers) also possibly influences outcome. This also has 
to do with (1) a high experience with the cheaper technique of 
TLM and (2) the limited availability of the operating robot due 
to a high frequency of use by other departments, i.e., urology and 
gynecology.
cOnclUsiOn
This multi-institutional retrospective case series confirms favora-
ble oncologic and functional outcomes of TORS for selected head 
and neck malignancies, both in the primary and in the salvage 
setting. Although we observed a trend toward higher DFS and 
OS in the up-front TORS group when compared to the salvage 
TORS group, these differences in oncologic outcome did not 
reach statistical significance. This finding supports TORS as a 
valuable alternative to salvage open en bloc surgery and confirms 
its additional role in the treatment of this difficult to treat salvage 
patient group.
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